|
Price: $91.8200
$-1.88 
-2.004%
|
| Day's High:
| $93.845
| Week Perf:
| -3.2 %
|
| Day's Low: |
$ 92.45 |
30 Day Perf: |
-16.47 % |
| Volume (M): |
70 |
52 Wk High: |
$ 129.50 |
| Volume (M$): |
$ 6,510 |
52 Wk Avg: |
$113.92 |
| Open: |
$95.55 |
52 Wk Low: |
$89.61 |
|
|
| Market Capitalization (Millions $) |
11,285 |
| Shares
Outstanding (Millions) |
123 |
| Employees |
11,500 |
| Revenues (TTM) (Millions $) |
2,755 |
| Net Income (TTM) (Millions $) |
270 |
| Cash Flow (TTM) (Millions $) |
250 |
| Capital Exp. (TTM) (Millions $) |
87 |
Revvity Inc
Company Address: 77 4th Avenue Waltham, 2451 MA
Company Phone Number: 663-6900 Stock Exchange / Ticker: NYSE RVTY
|
|
|
Customers Net Income fell by |
RVTY's Customers Net Profit Margin fell to |
-26.25 % |
2.71 %
|
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Business Update
Published Mon, Mar 3 2025 7:02 PM UTC
From Virus Vigilance to Financial Resilience: Revvity s Dual Path of Innovation In an era where healthcare precision and profitability walk hand-in-hand, Revvity, Inc. (NYSE: RVTY) strides forward as a formidable player in both arenas. The Massachusetts-based company recently announced a pivotal advancement with its subsidiary, EUROIMMUN, unveiling the CE-marked Anti-Measles...
|
| Business Update
Published Mon, Nov 18 2024 3:47 PM UTC
Revvity Inc. Announces Strategic Developments: Investor Day, New TB Testing Automation, and Upcoming Financial Call WALTHAM, Mass. Revvity, Inc. (NYSE: RVTY), a pioneering force in the biotechnological landscape, has announced a trifecta of significant corporate initiatives, emphasizing its commitment to innovation and stakeholder engagement. These announcements include ...
|
| Business Update
Published Wed, Oct 2 2024 12:47 PM UTC
In a significant move for Alzheimer s disease management, Revvity, Inc. (NYSE: RVTY) has announced the launch of its groundbreaking in-vitro diagnostic tool, the EURORealTime? APOE assay. This innovative assay, now available in various European countries that accept the CE mark, is designed to accurately genotype the APOE gene, a crucial step in assessing a patient?s risk fo...
|
| Revvity Inc
Navigating the Financial Landscape: Revvity Inc.?s Mixed Bag of Results
By
As I comb through the latest financial results from Revvity Inc. (NYSE: RVTY), it becomes clear that the company is exhibiting a unique dichotomy in its performance. The financial period ending June 30, 2024, has brought both challenges and successes, and while revenue has dipped, the overall earnings picture tells a different story.
Let's start with the numbers. Although Revvity's revenue has decreased by 2.45% year-on-year to $691.69 million, the most striking highlight of this report is the substantial increase in earnings per share (EPS), which soared by 60.71% to $0.45. This increase is even more remarkable when compared to the previous reporting period, where EPS more than doubled from $0.21. It?s a testament to the company?s ability to enhance profitability even in a challenging revenue environment.
|
| Dividend
Published Fri, Jul 26 2024 7:17 AM UTC
In a recent press release, Revvity (NYSE: RVTY) announced its declaration of a regular quarterly dividend of $0.07 per share of common stock. This news comes amidst positive market performance, with Revvity Inc stock witnessing significant growth in recent weeks.
Revvity s Quarterly Dividend Announcement:
WALTHAM, Mass. The Board of Directors of Rev...
|
| Per Share |
Current |
| Earnings (TTM) |
2.22 $ |
| Revenues (TTM) |
22.42 $
|
| Cash Flow (TTM) |
2.03 $ |
| Cash |
9.47 $
|
| Book Value |
62.38 $
|
| Dividend (TTM) |
0.28 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
2.22 $
|
| Revenues (TTM) |
22.42 $ |
| Cash Flow (TTM) |
2.03 $ |
| Cash |
9.47 $
|
| Book Value |
62.38 $ |
| Dividend (TTM) |
0.28 $ |
|
|
| |
| Product |
|
 87.53 % |
of total Revenue |
| Service |
|
12.47 % |
of total Revenue |
| Diagnostics |
|
56.01 % |
of total Revenue |
| Life Sciences |
|
43.99 % |
of total Revenue |
| Reportable Revenue |
|
100 % |
of total Revenue |
| Reportable Revenue Diagnostics |
|
56.04 % |
of total Revenue |
| Reportable Revenue Life Sciences |
|
43.99 % |
of total Revenue |
| Revenue Purchase Accounting Adjustments Reportable Revenue |
|
-0.03 % |
of total Revenue |
|
|
4.68%